Empery Asset Management's 9.99% Stake in X4 Pharmaceuticals

Empery Asset Management, LP, along with Ryan M. Lane and Martin D. Hoe, filed a Schedule 13G indicating a 9.99% beneficial ownership in X4 Pharmaceuticals, Inc. The ownership includes common stock and warrants exercisable into common stock, subject to a blocker that prevents the exercise of warrants if it would result in ownership exceeding 9.99%. The filing, made under Rule 13d-1(b), reflects the collective holdings of the Empery Funds managed by Empery Asset Management. The reporting persons disclaim beneficial ownership of the shares held by each other except to the extent of their pecuniary interest.